Collection and Storage of Tissue and Blood Samples From Patients With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02474160|
Recruitment Status : Recruiting
First Posted : June 17, 2015
Last Update Posted : May 6, 2021
|Condition or disease||Intervention/treatment|
|Lymphoma Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Plasma Cell Myeloma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Plasma Cell Myeloma||Other: Cytology Specimen Collection Procedure|
I. To procure biologic tissues and materials to generate preclinical models of cancer.
Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)|
|Actual Study Start Date :||May 15, 2015|
|Estimated Primary Completion Date :||May 4, 2022|
Ancillary-correlative (tissue and blood procurement)
Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
Other: Cytology Specimen Collection Procedure
Procurement of tissue and blood samples
Other Name: Cytologic Sampling
- Procurement of tissue and blood specimens for research purposes [ Time Frame: Up to 5 years ]Tissues and venous blood will be stored, implanted immediately to generate patient-derived xenografts (which require fresh, viable cells), or placed immediately into in vitro cell culture to generate patient-derived cell lines (which require fresh, viable cells).
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02474160
|Principal Investigator:||James H Doroshow||National Cancer Institute LAO|